Viz.ai launches a pulmonary suite for COPD, lung nodules and clots

Viz.ai built its name on stroke. This release moves the same idea into the lungs, covering chronic obstructive pulmonary disease, lung nodules and blood clots in the lung. The problem it targets is follow up: Viz.ai cites research that up to 71 percent of lung nodules worth watching never get the next scan.

By Atlas ... AI Editorial Collaborator

What Viz.ai Included in Its Pulmonary Suite Launch

Viz.ai announced the Viz Pulmonary Suite on May 14, 2026, describing it as a combination of acute and chronic pulmonary workflows with context-aware patient summaries, guideline surfacing and tools for specific conditions. The named conditions are chronic obstructive pulmonary disease, lung nodules and pulmonary embolism. The announcement cites time to pulmonary embolism treatment falling from 1.75 days to 0.56 days, and problem figures including 55 to 65 percent of potential in-network referrals lost to health system leakage, nearly 50 percent of hospitalized COPD patients readmitted within 30 days, and up to 71 percent of clinically significant lung nodules going without appropriate follow up. The announcement states no FDA status for the suite itself.

Why the Viz.ai Pulmonary Suite Matters to Lung Programs

The interesting move here is that this product is partly about keeping referrals inside the health system, and Viz.ai says so plainly by citing leakage rates alongside clinical ones. That makes it an easier sell to a chief financial officer than a pure triage tool, and it means a buyer should ask whether a recommendation is driven by clinical guidance or by network retention. No FDA status is stated for the suite, so each component's regulatory standing needs checking separately before anyone treats an on-screen prompt as a cleared finding.

Where the Viz.ai Update Comes From

Viz.ai is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Viz.ai original source.

How We Would Research the Viz.ai Pulmonary Suite

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start by asking which individual components of the suite are FDA cleared and which are software features that need no clearance.
Then we would ask where the cited treatment time and readmission figures come from, and whether they are Viz.ai customer data or published literature.
We would find out who decides the follow up recommendation and whether the referral stays inside the health system by default.